ArticleFrontiers in medicine2026
Lipemia retinalis secondary to pituitary neuroendocrine tumor: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report presents a 31-year-old male patient with lipemia retinalis secondary to a pituitary neuroendocrine tumor (PitNET). The patient presented with a 3-year history of progressive facial changes and enlargement of the hands and feet. Physical examination revealed typical signs of acromegaly. Cranial magnetic resonance imaging (MRI) confirmed a pituitary tumor. Laboratory examinations revealed significant elevations in growth hormone, insulin-like growth factor-1 (IGF-1), and serum lipid levels, along with chylous blood. Bilateral fundus examination showed characteristic creamy-pink discoloration of retinal arteries and veins, as well as a darkened retina with slight salmon-pink discoloration. After treatment with lipid-lowering therapy, glycemic control, and pituitary tumor resection, the patient's serum lipid levels, blood glucose, and growth hormone levels returned to normal, and the fundus manifestations resolved completely. Lipemia retinalis is an uncommon ocular disorder, and its occurrence secondary to a pituitary tumor is extremely rare. Clinicians are advised to closely monitor lipid metabolism and ocular manifestations in patients with pituitary tumors. Early identification of lipemia retinalis can help prevent serious adverse outcomes such as retinal vascular occlusion and systemic vascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.